Novartis: results of breast cancer analysis

(CercleFinance.com) - Novartis Kisqali shows increased benefit in a new analysis, reducing the risk of recurrence by 28.
5% in a large population of patients with early-stage breast cancer.

The invasive disease-free survival benefit continued to increase after the end of the three-year treatment period in all patient subgroups, including those with node-negative disease.

As we await regulatory action from health authorities around the world, we are very encouraged by these long-term results from NATALEE showing an increased efficacy benefit for Kisqali, Novartis said.

A large number of people diagnosed with HR+/HER2- early breast cancer remain at risk of recurrence, and these results add to the growing body of evidence supporting Kisqali's potential to consistently reduce this risk in a broad population, including patients with node-negative disease who have few options beyond ET. '

Novartis has submitted NATALEE data to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2023, and FDA regulatory action is expected in Q3.


Copyright (c) 2024 CercleFinance.com. All rights reserved.